SPG11 antibody (C-Term)

Catalog No. ABIN6991060

Product Details anti-SPG11 Antibody

Target: SPG11 (Spastic Paraplegia 11 (Autosomal Recessive) (SPG11))

Binding Specificity: AA 2360-2410, C-Term

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SPG11 antibody is un-conjugated

Application: ELISA, Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: SPG11 Antibody is affinity chromatography purified via peptide column.

Immunogen: SPG11 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human SPG11. The immunogen is located within amino acids 2360 - 2410 of SPG11.

Isotype: IgG

Application Details

Application Notes: SPG11 antibody can be used for detection of SPG11 by Western blot at 0.5 - 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL.

Antibody validated: Western Blot in mouse samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: SPG11 Antibody is supplied in PBS containing 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,4 °C

Storage Comment: SPG11 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Target Details for SPG11

Target: SPG11 (Spastic Paraplegia 11 (Autosomal Recessive) (SPG11))

Alternative Name: SPG11 (SPG11 Products)

Synonyms: 6030465E24Rik antibody, A330015I11 antibody, C530005A01Rik antibody, KIAA1840 antibody, RGD1562529 antibody, SPG11, spatacsin vesicle trafficking associated antibody, Spg11 antibody, SPG11 antibody

Background: SPG11 Antibody: Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders.  Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a relatively frequent form of complicated hereditary spastic paraplegia (cHSP) in which mental retardation and muscle stiffness at onset are followed by slowly progressive paraparesis and cognitive deterioration. Mutations of the SPG11 gene encoding the spatacsin protein have been identified as a major cause of HSP-TCC. Spatacsin is a potential transmembrane protein that is phosphorylated upon DNA damage. It is expressed in all structures of the brain, with a high expression in the cerebellum. SPG11 mutations may occur more frequently in familial than sporadic forms of cHSP without TCC. Kjellin syndrome is found to be associated with mutations in not only the SPG15 gene but also SPG11 gene.  Recent studies show Parkinsonism may initiate SPG11-linked HSP TCC and that SPG11 may cause juvenile Parkinsonism.

Gene ID: 80208

UniProt: Q96JI7